ID   ACLY_HUMAN              Reviewed;        1101 AA.
AC   P53396; B4DIM0; B4E3P0; Q13037; Q9BRL0;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 3.
DT   10-MAY-2017, entry version 185.
DE   RecName: Full=ATP-citrate synthase;
DE            EC=2.3.3.8;
DE   AltName: Full=ATP-citrate (pro-S-)-lyase;
DE            Short=ACL;
DE   AltName: Full=Citrate cleavage enzyme;
GN   Name=ACLY;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ASP-175.
RC   TISSUE=Liver;
RX   PubMed=1371749; DOI=10.1111/j.1432-1033.1992.tb16659.x;
RA   Elshourbagy N.A., Near J.C., Kmetz P.J., Wells T.N.C., Groot P.H.E.,
RA   Saxty B.A., Hughes S.A., Franklin M., Gloger I.S.;
RT   "Cloning and expression of a human ATP-citrate lyase cDNA.";
RL   Eur. J. Biochem. 204:491-499(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ASP-175.
RC   TISSUE=Liver;
RX   PubMed=9116495; DOI=10.1006/prep.1996.0668;
RA   Lord K.A., Wang X.M., Simmons S.J., Bruckner R.C., Loscig J.,
RA   O'Connor B., Bentley R., Smallwood A., Chadwick C.C., Stevis P.E.,
RA   Ciccarelli R.B.;
RT   "Variant cDNA sequences of human ATP:citrate lyase: cloning,
RT   expression, and purification from baculovirus-infected insect cells.";
RL   Protein Expr. Purif. 9:133-141(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3), AND VARIANT
RP   ASP-175.
RC   TISSUE=Hippocampus, and Uterus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R.,
RA   Gnerre S., Goldstein S., Grafham D.V., Grocock R., Hafez N.,
RA   Hagopian D.S., Hart E., Norman C.H., Humphray S., Jaffe D.B.,
RA   Jones M., Kamal M., Khodiyar V.K., LaButti K., Laird G., Lehoczky J.,
RA   Liu X., Lokyitsang T., Loveland J., Lui A., Macdonald P., Major J.E.,
RA   Matthews L., Mauceli E., McCarroll S.A., Mihalev A.H., Mudge J.,
RA   Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., Schwartz D.C.,
RA   Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in
RT   the human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   ENZYME REGULATION, AND PHOSPHORYLATION.
RX   PubMed=10653665; DOI=10.1021/bi992159y;
RA   Potapova I.A., El-Maghrabi M.R., Doronin S.V., Benjamin W.B.;
RT   "Phosphorylation of recombinant human ATP:citrate lyase by cAMP-
RT   dependent protein kinase abolishes homotropic allosteric regulation of
RT   the enzyme by citrate and increases the enzyme activity. Allosteric
RT   activation of ATP:citrate lyase by phosphorylated sugars.";
RL   Biochemistry 39:1169-1179(2000).
RN   [7]
RP   ISGYLATION.
RX   PubMed=16139798; DOI=10.1016/j.bbrc.2005.08.132;
RA   Giannakopoulos N.V., Luo J.K., Papov V., Zou W., Lenschow D.J.,
RA   Jacobs B.S., Borden E.C., Li J., Virgin H.W., Zhang D.E.;
RT   "Proteomic identification of proteins conjugated to ISG15 in mouse and
RT   human cells.";
RL   Biochem. Biophys. Res. Commun. 336:496-506(2005).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-131 AND TYR-682, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer
RT   cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-481, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-481, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17924679; DOI=10.1021/pr070152u;
RA   Yu L.R., Zhu Z., Chan K.C., Issaq H.J., Dimitrov D.S., Veenstra T.D.;
RT   "Improved titanium dioxide enrichment of phosphopeptides from HeLa
RT   cells and high confident phosphopeptide identification by cross-
RT   validation of MS/MS and MS/MS/MS spectra.";
RL   J. Proteome Res. 6:4150-4162(2007).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-481, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-455; SER-481 AND
RP   SER-1100, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-481; THR-639; SER-663;
RP   TYR-682; SER-839 AND SER-1100, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-481, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [16]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-546; LYS-554; LYS-948;
RP   LYS-968 AND LYS-1077, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-455 AND SER-481, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-455 AND SER-481, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-455; SER-459 AND
RP   SER-481, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [21]
RP   FUNCTION, ACETYLATION AT LYS-540; LYS-546 AND LYS-554, UBIQUITINATION
RP   AT LYS-540; LYS-546 AND LYS-554, AND MUTAGENESIS OF LYS-540; LYS-546
RP   AND LYS-554.
RX   PubMed=23932781; DOI=10.1016/j.molcel.2013.07.002;
RA   Lin R., Tao R., Gao X., Li T., Zhou X., Guan K.L., Xiong Y., Lei Q.Y.;
RT   "Acetylation stabilizes ATP-citrate lyase to promote lipid
RT   biosynthesis and tumor growth.";
RL   Mol. Cell 51:506-518(2013).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-455 AND SER-481, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 1-425 AND 487-820 IN COMPLEX
RP   WITH CITRATE, AND CITRATE-BINDING SITES.
RX   PubMed=20558738; DOI=10.1074/jbc.M109.078667;
RA   Sun T., Hayakawa K., Bateman K.S., Fraser M.E.;
RT   "Identification of the citrate-binding site of human ATP-citrate lyase
RT   using X-ray crystallography.";
RL   J. Biol. Chem. 285:27418-27428(2010).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 1-817 IN COMPLEX WITH ADP.
RX   PubMed=22102020; DOI=10.1107/S1744309111028363;
RA   Sun T., Hayakawa K., Fraser M.E.;
RT   "ADP-Mg2+ bound to the ATP-grasp domain of ATP-citrate lyase.";
RL   Acta Crystallogr. F 67:1168-1172(2011).
CC   -!- FUNCTION: ATP-citrate synthase is the primary enzyme responsible
CC       for the synthesis of cytosolic acetyl-CoA in many tissues. Has a
CC       central role in de novo lipid synthesis. In nervous tissue it may
CC       be involved in the biosynthesis of acetylcholine.
CC       {ECO:0000269|PubMed:23932781}.
CC   -!- CATALYTIC ACTIVITY: ADP + phosphate + acetyl-CoA + oxaloacetate =
CC       ATP + citrate + CoA.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- ENZYME REGULATION: Phosphorylation results in a 6-fold increase in
CC       V(max) and the conversion of citrate dependence from sigmoidal to
CC       hyperbolic. Fructose 6-phosphate (F6P) is also a potent activator.
CC       {ECO:0000269|PubMed:10653665}.
CC   -!- SUBUNIT: Homotetramer. {ECO:0000269|PubMed:20558738,
CC       ECO:0000269|PubMed:22102020}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P53396-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P53396-2; Sequence=VSP_042201;
CC       Name=3;
CC         IsoId=P53396-3; Sequence=VSP_057230, VSP_042201;
CC         Note=No experimental confirmation available.;
CC   -!- PTM: ISGylated. {ECO:0000269|PubMed:16139798}.
CC   -!- PTM: Acetylated at Lys-540, Lys-546 and Lys-554 by KAT2B/PCAF.
CC       Acetylation is promoted by glucose and stabilizes the protein,
CC       probably by preventing ubiquitination at the same sites.
CC       Acetylation promotes de novo lipid synthesis. Deacetylated by
CC       SIRT2. {ECO:0000269|PubMed:23932781}.
CC   -!- PTM: Ubiquitinated at Lys-540, Lys-546 and Lys-554 by UBR4,
CC       leading to its degradation. Ubiquitination is probably inhibited
CC       by acetylation at same site (Probable).
CC       {ECO:0000305|PubMed:23932781}.
CC   -!- SIMILARITY: In the N-terminal section; belongs to the
CC       succinate/malate CoA ligase beta subunit family. {ECO:0000305}.
CC   -!- SIMILARITY: In the C-terminal section; belongs to the
CC       succinate/malate CoA ligase alpha subunit family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/ACLYID50486ch17q21.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X64330; CAA45614.1; -; mRNA.
DR   EMBL; U18197; AAB60340.1; -; mRNA.
DR   EMBL; AK295675; BAG58532.1; -; mRNA.
DR   EMBL; AK304802; BAG65552.1; -; mRNA.
DR   EMBL; AC091172; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC125257; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC006195; AAH06195.1; -; mRNA.
DR   CCDS; CCDS11412.1; -. [P53396-1]
DR   CCDS; CCDS11413.1; -. [P53396-2]
DR   PIR; S21173; S21173.
DR   RefSeq; NP_001087.2; NM_001096.2. [P53396-1]
DR   RefSeq; NP_001290203.1; NM_001303274.1.
DR   RefSeq; NP_001290204.1; NM_001303275.1.
DR   RefSeq; NP_942127.1; NM_198830.1. [P53396-2]
DR   RefSeq; XP_005257452.1; XM_005257395.1. [P53396-1]
DR   UniGene; Hs.387567; -.
DR   PDB; 3MWD; X-ray; 2.10 A; A=1-425, B=487-820.
DR   PDB; 3MWE; X-ray; 2.20 A; A=1-425, B=487-821.
DR   PDB; 3PFF; X-ray; 2.30 A; A=1-817.
DR   PDBsum; 3MWD; -.
DR   PDBsum; 3MWE; -.
DR   PDBsum; 3PFF; -.
DR   ProteinModelPortal; P53396; -.
DR   SMR; P53396; -.
DR   BioGrid; 106563; 60.
DR   IntAct; P53396; 13.
DR   MINT; MINT-3019895; -.
DR   STRING; 9606.ENSP00000253792; -.
DR   BindingDB; P53396; -.
DR   ChEMBL; CHEMBL3720; -.
DR   SwissLipids; SLP:000000779; -.
DR   iPTMnet; P53396; -.
DR   PhosphoSitePlus; P53396; -.
DR   SwissPalm; P53396; -.
DR   BioMuta; ACLY; -.
DR   DMDM; 116241237; -.
DR   EPD; P53396; -.
DR   MaxQB; P53396; -.
DR   PaxDb; P53396; -.
DR   PeptideAtlas; P53396; -.
DR   PRIDE; P53396; -.
DR   DNASU; 47; -.
DR   Ensembl; ENST00000352035; ENSP00000253792; ENSG00000131473. [P53396-1]
DR   Ensembl; ENST00000353196; ENSP00000345398; ENSG00000131473. [P53396-2]
DR   Ensembl; ENST00000393896; ENSP00000377474; ENSG00000131473. [P53396-2]
DR   Ensembl; ENST00000537919; ENSP00000445349; ENSG00000131473. [P53396-3]
DR   Ensembl; ENST00000590151; ENSP00000466259; ENSG00000131473. [P53396-1]
DR   GeneID; 47; -.
DR   KEGG; hsa:47; -.
DR   UCSC; uc002hyg.4; human. [P53396-1]
DR   CTD; 47; -.
DR   DisGeNET; 47; -.
DR   GeneCards; ACLY; -.
DR   HGNC; HGNC:115; ACLY.
DR   HPA; CAB007783; -.
DR   HPA; HPA022434; -.
DR   HPA; HPA022953; -.
DR   HPA; HPA022959; -.
DR   HPA; HPA028758; -.
DR   MIM; 108728; gene.
DR   neXtProt; NX_P53396; -.
DR   OpenTargets; ENSG00000131473; -.
DR   PharmGKB; PA24441; -.
DR   eggNOG; KOG1254; Eukaryota.
DR   eggNOG; COG0045; LUCA.
DR   eggNOG; COG0074; LUCA.
DR   eggNOG; COG0372; LUCA.
DR   GeneTree; ENSGT00530000063275; -.
DR   HOGENOM; HOG000151479; -.
DR   HOVERGEN; HBG003318; -.
DR   InParanoid; P53396; -.
DR   KO; K01648; -.
DR   OMA; EGRVWTM; -.
DR   OrthoDB; EOG091G0OYH; -.
DR   PhylomeDB; P53396; -.
DR   TreeFam; TF300560; -.
DR   BioCyc; MetaCyc:HS05535-MONOMER; -.
DR   BRENDA; 2.3.3.8; 2681.
DR   Reactome; R-HSA-163765; ChREBP activates metabolic gene expression.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   Reactome; R-HSA-75105; Fatty Acyl-CoA Biosynthesis.
DR   SABIO-RK; P53396; -.
DR   SIGNOR; P53396; -.
DR   ChiTaRS; ACLY; human.
DR   EvolutionaryTrace; P53396; -.
DR   GenomeRNAi; 47; -.
DR   PRO; PR:P53396; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000131473; -.
DR   CleanEx; HS_ACLY; -.
DR   ExpressionAtlas; P53396; baseline and differential.
DR   Genevisible; P53396; HS.
DR   GO; GO:0035578; C:azurophil granule lumen; TAS:Reactome.
DR   GO; GO:0009346; C:citrate lyase complex; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:1904813; C:ficolin-1-rich granule lumen; TAS:Reactome.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0005524; F:ATP binding; TAS:BHF-UCL.
DR   GO; GO:0003878; F:ATP citrate synthase activity; IDA:BHF-UCL.
DR   GO; GO:0048037; F:cofactor binding; IEA:InterPro.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006085; P:acetyl-CoA biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0006695; P:cholesterol biosynthetic process; TAS:BHF-UCL.
DR   GO; GO:0006101; P:citrate metabolic process; IDA:BHF-UCL.
DR   GO; GO:0006633; P:fatty acid biosynthetic process; IBA:GO_Central.
DR   GO; GO:0008610; P:lipid biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0035338; P:long-chain fatty-acyl-CoA biosynthetic process; TAS:Reactome.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   GO; GO:0006107; P:oxaloacetate metabolic process; IDA:BHF-UCL.
DR   GO; GO:0031325; P:positive regulation of cellular metabolic process; TAS:Reactome.
DR   Gene3D; 1.10.230.10; -; 1.
DR   Gene3D; 1.10.580.10; -; 1.
DR   Gene3D; 3.40.50.261; -; 2.
DR   InterPro; IPR014608; ATP-citrate_synthase.
DR   InterPro; IPR017440; Cit_synth/succinyl-CoA_lig_AS.
DR   InterPro; IPR032263; Citrate-bd.
DR   InterPro; IPR016142; Citrate_synth-like_lrg_a-sub.
DR   InterPro; IPR016143; Citrate_synth-like_sm_a-sub.
DR   InterPro; IPR002020; Citrate_synthase.
DR   InterPro; IPR033847; Citrt_syn/SCS-alpha_CS.
DR   InterPro; IPR003781; CoA-bd.
DR   InterPro; IPR005811; CoA_ligase.
DR   InterPro; IPR016040; NAD(P)-bd_dom.
DR   InterPro; IPR017866; Succ-CoA_synthase_bsu_CS.
DR   InterPro; IPR016102; Succinyl-CoA_synth-like.
DR   Pfam; PF16114; Citrate_bind; 1.
DR   Pfam; PF00285; Citrate_synt; 1.
DR   Pfam; PF02629; CoA_binding; 1.
DR   Pfam; PF00549; Ligase_CoA; 1.
DR   PIRSF; PIRSF036511; ATP_citrt_syn; 1.
DR   SMART; SM00881; CoA_binding; 1.
DR   SUPFAM; SSF48256; SSF48256; 2.
DR   SUPFAM; SSF51735; SSF51735; 1.
DR   SUPFAM; SSF52210; SSF52210; 1.
DR   PROSITE; PS01216; SUCCINYL_COA_LIG_1; 1.
DR   PROSITE; PS00399; SUCCINYL_COA_LIG_2; 1.
DR   PROSITE; PS01217; SUCCINYL_COA_LIG_3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP-binding;
KW   Complete proteome; Cytoplasm; Isopeptide bond; Lipid biosynthesis;
KW   Lipid metabolism; Magnesium; Metal-binding; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Reference proteome; Transferase;
KW   Ubl conjugation.
FT   CHAIN         1   1101       ATP-citrate synthase.
FT                                /FTId=PRO_0000102781.
FT   DOMAIN        4    265       ATP-grasp.
FT   NP_BIND      66     67       ATP.
FT   NP_BIND     109    111       ATP.
FT   NP_BIND     701    721       ATP. {ECO:0000250}.
FT   NP_BIND     752    778       ATP. {ECO:0000250}.
FT   REGION      779    789       CoA-binding. {ECO:0000255}.
FT   ACT_SITE    760    760       Tele-phosphohistidine intermediate.
FT                                {ECO:0000250}.
FT   METAL       201    201       Magnesium. {ECO:0000250}.
FT   METAL       203    203       Magnesium. {ECO:0000250}.
FT   METAL       718    718       Magnesium. {ECO:0000250}.
FT   BINDING      58     58       ATP.
FT   BINDING     118    118       ATP.
FT   BINDING     346    346       Citrate; via amide nitrogen.
FT                                {ECO:0000269|PubMed:20558738}.
FT   BINDING     348    348       Citrate. {ECO:0000269|PubMed:20558738}.
FT   BINDING     379    379       Citrate. {ECO:0000269|PubMed:20558738}.
FT   MOD_RES     131    131       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:15592455}.
FT   MOD_RES     263    263       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q91V92}.
FT   MOD_RES     447    447       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:P16638}.
FT   MOD_RES     451    451       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P16638}.
FT   MOD_RES     455    455       Phosphoserine; by PKA and PKB/AKT1 or
FT                                PKB/AKT2. {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     459    459       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     481    481       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:17924679,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     540    540       N6-acetyllysine; alternate.
FT                                {ECO:0000269|PubMed:23932781}.
FT   MOD_RES     546    546       N6-acetyllysine; alternate.
FT                                {ECO:0000244|PubMed:19608861,
FT                                ECO:0000269|PubMed:23932781}.
FT   MOD_RES     554    554       N6-acetyllysine; alternate.
FT                                {ECO:0000244|PubMed:19608861,
FT                                ECO:0000269|PubMed:23932781}.
FT   MOD_RES     639    639       Phosphothreonine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     663    663       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     682    682       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:15592455,
FT                                ECO:0000244|PubMed:19369195}.
FT   MOD_RES     839    839       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     948    948       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     968    968       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     978    978       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q91V92}.
FT   MOD_RES    1077   1077       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    1100   1100       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19369195}.
FT   CROSSLNK    540    540       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin);
FT                                alternate. {ECO:0000305|PubMed:23932781}.
FT   CROSSLNK    546    546       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin);
FT                                alternate. {ECO:0000305|PubMed:23932781}.
FT   CROSSLNK    554    554       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin);
FT                                alternate. {ECO:0000305|PubMed:23932781}.
FT   VAR_SEQ      95    355       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_057230.
FT   VAR_SEQ     476    485       Missing (in isoform 2 and isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_042201.
FT   VARIANT     175    175       E -> D (in dbSNP:rs2304497).
FT                                {ECO:0000269|PubMed:1371749,
FT                                ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:9116495}.
FT                                /FTId=VAR_028230.
FT   MUTAGEN     540    540       K->R,Q: Decreased acetylation and
FT                                increased de novo lipid synthesis; when
FT                                associated with R,Q-546 and R,Q-554.
FT                                {ECO:0000269|PubMed:23932781}.
FT   MUTAGEN     546    546       K->R,Q: Decreased acetylation and
FT                                increased de novo lipid synthesis; when
FT                                associated with R,Q-540 and R,Q-554.
FT                                {ECO:0000269|PubMed:23932781}.
FT   MUTAGEN     554    554       K->R,Q: Decreased acetylation and
FT                                increased de novo lipid synthesis; when
FT                                associated with R,Q-540 and R,Q-546.
FT                                {ECO:0000269|PubMed:23932781}.
FT   CONFLICT     75     75       N -> D (in Ref. 1; CAA45614).
FT                                {ECO:0000305}.
FT   CONFLICT    111    111       V -> A (in Ref. 1; CAA45614).
FT                                {ECO:0000305}.
FT   CONFLICT    245    245       E -> V (in Ref. 1; CAA45614).
FT                                {ECO:0000305}.
FT   CONFLICT    419    423       LGHRP -> WAPA (in Ref. 1; CAA45614).
FT                                {ECO:0000305}.
FT   CONFLICT    442    444       SGS -> QRE (in Ref. 1; CAA45614).
FT                                {ECO:0000305}.
FT   CONFLICT    457    459       SES -> YESMVDEV (in Ref. 1; CAA45614).
FT                                {ECO:0000305}.
FT   CONFLICT    653    656       RPGS -> PQAA (in Ref. 1; CAA45614).
FT                                {ECO:0000305}.
FT   CONFLICT    728    728       C -> S (in Ref. 1; CAA45614).
FT                                {ECO:0000305}.
FT   CONFLICT    872    872       V -> A (in Ref. 1; CAA45614).
FT                                {ECO:0000305}.
FT   CONFLICT    916    919       AGKD -> TAVE (in Ref. 1; CAA45614).
FT                                {ECO:0000305}.
FT   STRAND        3      6       {ECO:0000244|PDB:3MWD}.
FT   HELIX         8     18       {ECO:0000244|PDB:3MWD}.
FT   STRAND       32     34       {ECO:0000244|PDB:3MWD}.
FT   HELIX        40     46       {ECO:0000244|PDB:3MWD}.
FT   HELIX        48     51       {ECO:0000244|PDB:3MWD}.
FT   STRAND       55     59       {ECO:0000244|PDB:3MWD}.
FT   TURN         66     70       {ECO:0000244|PDB:3MWD}.
FT   STRAND       73     76       {ECO:0000244|PDB:3MWD}.
FT   HELIX        78     85       {ECO:0000244|PDB:3MWD}.
FT   TURN         86     90       {ECO:0000244|PDB:3MWD}.
FT   STRAND       92     95       {ECO:0000244|PDB:3MWD}.
FT   STRAND       98    101       {ECO:0000244|PDB:3MWD}.
FT   STRAND      105    109       {ECO:0000244|PDB:3MWD}.
FT   HELIX       115    117       {ECO:0000244|PDB:3MWD}.
FT   STRAND      118    126       {ECO:0000244|PDB:3MWD}.
FT   STRAND      129    137       {ECO:0000244|PDB:3MWD}.
FT   HELIX       140    142       {ECO:0000244|PDB:3MWE}.
FT   HELIX       145    148       {ECO:0000244|PDB:3MWD}.
FT   STRAND      149    155       {ECO:0000244|PDB:3MWD}.
FT   HELIX       162    167       {ECO:0000244|PDB:3MWD}.
FT   TURN        168    172       {ECO:0000244|PDB:3MWD}.
FT   TURN        175    177       {ECO:0000244|PDB:3MWD}.
FT   HELIX       178    194       {ECO:0000244|PDB:3MWD}.
FT   STRAND      197    208       {ECO:0000244|PDB:3MWD}.
FT   STRAND      211    214       {ECO:0000244|PDB:3MWD}.
FT   STRAND      217    222       {ECO:0000244|PDB:3MWD}.
FT   HELIX       223    225       {ECO:0000244|PDB:3MWD}.
FT   HELIX       226    233       {ECO:0000244|PDB:3MWD}.
FT   STRAND      242    244       {ECO:0000244|PDB:3MWD}.
FT   HELIX       248    258       {ECO:0000244|PDB:3MWD}.
FT   STRAND      260    269       {ECO:0000244|PDB:3MWD}.
FT   STRAND      274    277       {ECO:0000244|PDB:3MWD}.
FT   HELIX       282    294       {ECO:0000244|PDB:3MWD}.
FT   HELIX       298    300       {ECO:0000244|PDB:3MWD}.
FT   STRAND      303    309       {ECO:0000244|PDB:3MWD}.
FT   HELIX       313    326       {ECO:0000244|PDB:3MWD}.
FT   STRAND      336    340       {ECO:0000244|PDB:3MWD}.
FT   STRAND      346    348       {ECO:0000244|PDB:3MWD}.
FT   HELIX       350    363       {ECO:0000244|PDB:3MWD}.
FT   HELIX       365    370       {ECO:0000244|PDB:3MWD}.
FT   STRAND      373    378       {ECO:0000244|PDB:3MWD}.
FT   HELIX       384    398       {ECO:0000244|PDB:3MWD}.
FT   STRAND      402    405       {ECO:0000244|PDB:3MWD}.
FT   HELIX       413    418       {ECO:0000244|PDB:3MWD}.
FT   STRAND      499    503       {ECO:0000244|PDB:3MWD}.
FT   HELIX       506    518       {ECO:0000244|PDB:3MWD}.
FT   STRAND      525    530       {ECO:0000244|PDB:3MWD}.
FT   STRAND      536    543       {ECO:0000244|PDB:3MWD}.
FT   STRAND      546    555       {ECO:0000244|PDB:3MWD}.
FT   HELIX       556    562       {ECO:0000244|PDB:3MWD}.
FT   STRAND      568    571       {ECO:0000244|PDB:3MWD}.
FT   TURN        575    577       {ECO:0000244|PDB:3MWD}.
FT   HELIX       578    585       {ECO:0000244|PDB:3MWD}.
FT   STRAND      593    596       {ECO:0000244|PDB:3MWD}.
FT   HELIX       603    616       {ECO:0000244|PDB:3MWD}.
FT   STRAND      619    621       {ECO:0000244|PDB:3MWD}.
FT   STRAND      628    630       {ECO:0000244|PDB:3MWD}.
FT   TURN        631    633       {ECO:0000244|PDB:3MWD}.
FT   TURN        637    640       {ECO:0000244|PDB:3MWD}.
FT   HELIX       643    648       {ECO:0000244|PDB:3MWD}.
FT   TURN        649    652       {ECO:0000244|PDB:3MWD}.
FT   STRAND      656    662       {ECO:0000244|PDB:3MWD}.
FT   HELIX       664    677       {ECO:0000244|PDB:3MWD}.
FT   STRAND      681    686       {ECO:0000244|PDB:3MWD}.
FT   STRAND      689    692       {ECO:0000244|PDB:3MWD}.
FT   HELIX       697    705       {ECO:0000244|PDB:3MWD}.
FT   STRAND      712    722       {ECO:0000244|PDB:3MWD}.
FT   HELIX       723    732       {ECO:0000244|PDB:3MWD}.
FT   STRAND      740    745       {ECO:0000244|PDB:3MWD}.
FT   HELIX       768    770       {ECO:0000244|PDB:3MWD}.
FT   HELIX       772    781       {ECO:0000244|PDB:3MWD}.
FT   HELIX       790    792       {ECO:0000244|PDB:3MWD}.
FT   HELIX       793    806       {ECO:0000244|PDB:3MWD}.
SQ   SEQUENCE   1101 AA;  120839 MW;  12BB4416A30DC30C CRC64;
     MSAKAISEQT GKELLYKFIC TTSAIQNRFK YARVTPDTDW ARLLQDHPWL LSQNLVVKPD
     QLIKRRGKLG LVGVNLTLDG VKSWLKPRLG QEATVGKATG FLKNFLIEPF VPHSQAEEFY
     VCIYATREGD YVLFHHEGGV DVGDVDAKAQ KLLVGVDEKL NPEDIKKHLL VHAPEDKKEI
     LASFISGLFN FYEDLYFTYL EINPLVVTKD GVYVLDLAAK VDATADYICK VKWGDIEFPP
     PFGREAYPEE AYIADLDAKS GASLKLTLLN PKGRIWTMVA GGGASVVYSD TICDLGGVNE
     LANYGEYSGA PSEQQTYDYA KTILSLMTRE KHPDGKILII GGSIANFTNV AATFKGIVRA
     IRDYQGPLKE HEVTIFVRRG GPNYQEGLRV MGEVGKTTGI PIHVFGTETH MTAIVGMALG
     HRPIPNQPPT AAHTANFLLN ASGSTSTPAP SRTASFSESR ADEVAPAKKA KPAMPQDSVP
     SPRSLQGKST TLFSRHTKAI VWGMQTRAVQ GMLDFDYVCS RDEPSVAAMV YPFTGDHKQK
     FYWGHKEILI PVFKNMADAM RKHPEVDVLI NFASLRSAYD STMETMNYAQ IRTIAIIAEG
     IPEALTRKLI KKADQKGVTI IGPATVGGIK PGCFKIGNTG GMLDNILASK LYRPGSVAYV
     SRSGGMSNEL NNIISRTTDG VYEGVAIGGD RYPGSTFMDH VLRYQDTPGV KMIVVLGEIG
     GTEEYKICRG IKEGRLTKPI VCWCIGTCAT MFSSEVQFGH AGACANQASE TAVAKNQALK
     EAGVFVPRSF DELGEIIQSV YEDLVANGVI VPAQEVPPPT VPMDYSWARE LGLIRKPASF
     MTSICDERGQ ELIYAGMPIT EVFKEEMGIG GVLGLLWFQK RLPKYSCQFI EMCLMVTADH
     GPAVSGAHNT IICARAGKDL VSSLTSGLLT IGDRFGGALD AAAKMFSKAF DSGIIPMEFV
     NKMKKEGKLI MGIGHRVKSI NNPDMRVQIL KDYVRQHFPA TPLLDYALEV EKITTSKKPN
     LILNVDGLIG VAFVDMLRNC GSFTREEADE YIDIGALNGI FVLGRSMGFI GHYLDQKRLK
     QGLYRHPWDD ISYVLPEHMS M
//
